» Authors » William L Heyward

William L Heyward

Explore the profile of William L Heyward including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 698
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, et al.
Vaccine . 2018 Jan; 36(5):668-674. PMID: 29289383
Background: Hepatitis B virus infection remains an important public health problem in the United States. Currently approved alum-adjuvanted vaccines require three doses and have reduced immunogenicity in adults, particularly in...
2.
Janssen J, Jackson S, Heyward W, Janssen R
Vaccine . 2015 Jun; 33(31):3614-8. PMID: 26067185
Background: Immunologic response to a complete vaccine regimen of currently licensed alum-adjuvanted hepatitis B vaccines is reduced in several subpopulations, including older adults, men, obese persons, and smokers. Two phase...
3.
Janssen J, Heyward W, Martin J, Janssen R
Vaccine . 2015 Jan; 33(7):833-7. PMID: 25576215
Background: Many patients with chronic kidney disease (CKD) are hyporesponsive to currently licensed alum-adjuvanted hepatitis B vaccines, including Engerix-B(®) (HBsAg-Eng). Seroprotection rates (SPRs) are further reduced in CKD patients with...
4.
Janssen R, Mangoo-Karim R, Pergola P, Girndt M, Namini H, Rahman S, et al.
Vaccine . 2013 Jun; 31(46):5306-13. PMID: 23727422
Background: Hemodialysis patients are at increased risk of hepatitis B virus (HBV) infection and patients with chronic kidney disease (CKD) are commonly hyporesponsive to HBV vaccines. Current recommendations for CKD...
5.
Heyward W, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo M, et al.
Vaccine . 2013 Jun; 31(46):5300-5. PMID: 23727002
Background: The currently licensed hepatitis B vaccines have limitations including hyporesponsiveness in older adults, poor compliance, and the extended time for most persons to develop seroprotection (e.g. >6months). A vaccine...
6.
Halperin S, Ward B, Dionne M, Langley J, McNeil S, Smith B, et al.
Hum Vaccin Immunother . 2013 Apr; 9(7):1438-44. PMID: 23571179
An additional one to three doses of hepatitis B vaccine are recommended for nonresponders to an initial standard three-dose series. We compared the safety and immunogenicity of an investigational hepatitis...
7.
Halperin S, McNeil S, Langley J, Smith B, MacKinnon-Cameron D, McCall-Sani R, et al.
Vaccine . 2012 Jun; 30(36):5445-8. PMID: 22704926
Background: Previous studies have shown that two doses of an investigational hepatitis B vaccine consisting of hepatitis B surface antigen combined with an immunostimulatory phosphorothioate oligodeoxyribonucleotide adjuvant (HBV-ISS) given 8...
8.
Sablan B, Kim D, Barzaga N, Chow W, Cho M, Ahn S, et al.
Vaccine . 2012 Feb; 30(16):2689-96. PMID: 22342916
Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor...
9.
Halperin S, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al.
Vaccine . 2012 Feb; 30(15):2556-63. PMID: 22326642
Background: The currently licensed aluminum-hydroxide-adjuvanted hepatitis B vaccines require three doses over a 6-month period to achieve high rates of protection in adults. We compared tolerability and immunogenicity of two...
10.
B Gilbert P, Ackers M, Berman P, Francis D, Popovic V, Hu D, et al.
J Infect Dis . 2005 Aug; 192(6):974-83. PMID: 16107949
The first trial of the efficacy of a human immunodeficiency virus (HIV)-1 vaccine was conducted in North America and The Netherlands between 1998 and 2003. This multicenter, randomized, placebo-controlled trial...